Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective ...
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2003 as Fundamental Applied Biology and renamed in 2009, the company is dedicated to transforming cancer treatment through its next-generation antibody-drug conjugate (ADC) platform. Sutro's proprietary XpressCF+ technology integrates cell-free protein synthesis ...Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2003 as Fundamental Applied Biology and renamed in 2009, the company is dedicated to transforming cancer treatment through its next-generation antibody-drug conjugate (ADC) platform. Sutro's proprietary XpressCF+ technology integrates cell-free protein synthesis with site-specific conjugation, enabling rapid and efficient production of homogeneous ADCs with optimized drug-to-antibody ratios and improved therapeutic windows.
Sutro's pipeline includes two lead ADC candidates currently in Phase 1 clinical trials. STRO-001 targets CD74, an antigen highly expressed in multiple myeloma and non-Hodgkin lymphoma, and is designed to deliver a cytotoxic payload directly to cancer cells. STRO-002 targets folate receptor-alpha (FRα), which is overexpressed in ovarian and endometrial cancers, and has shown promise in early trials for these difficult-to-treat indications. Additionally, the company is advancing novel formats, such as dual-payload ADCs, to overcome tumor heterogeneity and combat drug resistance.
Beyond its internal pipeline, Sutro has established strategic collaborations with major pharmaceutical companies. A partnership with Merck focuses on developing cytokine derivatives for oncology and autoimmune applications, while an agreement with Celgene (now Bristol-Myers Squibb) aims to identify bispecific antibodies and ADCs in immuno-oncology. These partnerships validate Sutro's platform and provide non-dilutive funding and potential milestone payments.
Financially, as of the latest data (TTM), Sutro has a market capitalization of approximately $247 million. The company's revenue per share stands at $7.61, but it incurs significant research and development expenses (R&D to revenue ratio of 152%) and operating losses, leading to negative net income. However, with a strong cash position (cash per share of $15.48) and a healthy current ratio of 3.12, Sutro is well-capitalized to fund its clinical programs. The company employs 137 full-time staff, yet LinkedIn indicates a range of 201-500, possibly reflecting a broader base including contractors. Sutro has been recognized as a 'Best Place to Work' by BioSpace, highlighting its commitment to employee satisfaction and innovation.
Under the leadership of CEO Jane Chung, who took office in March 2025, Sutro continues to advance its mission of delivering precisely designed cancer therapeutics. With a focus on unmet medical needs, robust partnerships, and a cutting-edge platform, Sutro Biopharma is positioned to make a significant impact in oncology and beyond.
